Monitor for safety and biodistribution data in 2H 2026, which could de-risk the program and catalyze investor interest. Given the early stage, near-term trading may remain speculative.
Price Chart
Executive Summary
Radiopharm Theranostics has dosed the first patient in a Phase 1 trial of RAD 402, a first-in-class radiolabeled monoclonal antibody targeting KLK3 for advanced prostate cancer. The trial will assess safety, dosing, and preliminary efficacy, with data from the first two dose levels expected in the second half of 2026.
Key Facts
- First patient dosed in Phase 1 trial (NCT07259213) of RAD 402 for advanced prostate cancer.
- Trial is dose-escalation, designed to determine MTD and/or RP2D.
- Preclinical data show strong tumor targeting, minimal bone/marrow uptake, and hepatic clearance.
- Data from first two dose levels expected in 2H 2026.
- RAD 402 targets KLK3 (PSA-encoding gene), highly expressed in prostate cancer.
Financial Impact
No immediate financial impact; potential long-term value if clinical milestones are met.
Risk Factors
- Phase 1 trials carry high failure risk; safety or dosing issues could halt development.
- Limited market visibility due to OTC listing and small market cap ($54M), increasing volatility risk.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3263666 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | 6-K | — | awaiting T+5 | — | — |
Oct 20, 2026 6d ago | 6-K | $0.9900 | awaiting T+5 | — | $0.9960 (+0.61%) |
Oct 14, 2026 11d ago | SC 13G | $1.08 $0.9500 | ▼ −12.04% | ▼ −11.02% | $0.9960 (−7.78%) |
Oct 5, 2026 21d ago | 6-K | $1.27 $1.11 | ▼ −12.60% | ▼ −13.02% | $0.9960 (−21.57%) |
Oct 1, 2026 25d ago | 6-K | $1.48 $1.11 | ▼ −25.00% | ▼ −26.30% | $0.9960 (−32.70%) |
Sep 30, 2026 26d ago | 6-K | $1.62 $1.15 | ▼ −29.01% | ▼ −30.93% | $0.9960 (−38.52%) |
Sep 24, 2026 4w ago | EFFECT | $1.57 $1.48 | ▲ +5.85% | ▲ +5.43% | $0.9960 (+36.64%) |
Sep 22, 2026 4w ago | 6-K | $1.65 $1.52 | ▼ −7.88% | ▼ −6.69% | $0.9960 (−39.64%) |
Sep 14, 2026 6w ago | 6-K | $2.01 $1.61 | ▼ −19.90% | ▼ −20.01% | $0.9960 (−50.45%) |
Sep 11, 2026 6w ago | 6-K | $1.98 $1.65 | ▼ −16.67% | ▼ −16.45% | $0.9960 (−49.70%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers